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a b s t r a c t
Mutations in the Huntington locus (htt) have devastating consequences. Gain-of-poly-Q repeats in Htt
protein causes Huntington's disease (HD), while htt / mutants display early embryonic lethality.
Despite its importance, the function of Htt remains elusive. To address this, we compared more than
3700 compounds in three syngeneic mouse embryonic stem cell (mESC) lines: htt/ , extended poly-Q
(Htt-Q140/7), and wild-type mESCs (Htt-Q7/7) using untargeted metabolite proﬁling. While Htt-Q140/7
cells did not show major differences in cellular bioenergetics, we ﬁnd extensive metabolic aberrations in
htt / mESCs, including (i) complete failure of ATP production despite preservation of the mitochondrial
membrane potential; (ii) near-maximal glycolysis, with little or no glycolytic reserve; (iii) marked
ketogenesis; (iv) depletion of intracellular NTPs; (v) accelerated purine biosynthesis and salvage; and (vi)
loss of mitochondrial structural integrity. Together, our ﬁndings reveal that Htt is necessary for
mitochondrial structure and function from the earliest stages of embryogenesis, providing a molecular
explanation for htt / early embryonic lethality.
& 2014 Elsevier Inc. All rights reserved.
Introduction
The Huntington locus (htt) in the mammalian genome encodes
a large protein called Huntingtin (Htt). Htt protein is maternally
expressed from the ﬁrst cell stage in the fertilized egg and
subsequently is ubiquitously found in all cells of the embryo and
adult. Mutations affecting the locus have dramatic consequences
in both mouse and humans. Homozygote htt / embryos undergo
developmental arrest, fail to undergo proper gastrulation, lack a
proper node, display a shortened primitive streak, and exhibit an
impaired patterning of embryonic germ layers – early embryonic
lethality occurs by e7.0–7.5 (Duyao et al., 1995; Woda et al., 2005).
In contrast to the lethality of htt/ embryos, mutation of
a single htt allele that expands the poly-Q (CAG) repeat at the
N-terminal domain of Htt protein results in the dominantly
inherited Huntington's disease (HD) (Duyao et al., 1995; Jacobsen
et al., 2011). HD is a devastating neurodegenerative disease
typiﬁed by a progressive movement disorder, cognitive decline,
and psychological impairment due to the death of medium spiny
neurons in the striatum (Reiner et al., 1988), and other areas of the
brain (Tabrizi et al., 2011). Some aspects of the disease can be
recapitulated in rodent models by genetically increasing the length
of the poly-Q repeat. As a platform to investigate Htt loss- and
gain-of-function effects in the same genetic background, experi-
ments were performed in syngeneic knock-in mouse embryonic
stem cells (mESC) containing one copy of a humanized exon 1
(with an extended polyglutamine tract and adjacent proline-rich
region; Htt-Q140/Q7), as well as knockout (htt /) (Zheng et al.,
2012; Nasir et al., 1995), in comparison with mESC expressing the
mouse htt gene (Htt-Q7/7). Importantly, studies of htt/ mESC
afford an opportunity to assess Htt protein function because
viability is maintained as pluripotent cells, despite the lethality
that invariably ensues in htt / mice during embryogenesis.
The embryonic functions of the Htt protein remain essentially
unknown. Notwithstanding, Htt has been implicated in diverse cell
processes in multiple investigated cell types. These include, but
are not limited to trafﬁcking of growth factor complexes (del Toro
Contents lists available at ScienceDirect
journal homepage: www.elsevier.com/locate/developmentalbiology
Developmental Biology
http://dx.doi.org/10.1016/j.ydbio.2014.04.005
0012-1606/& 2014 Elsevier Inc. All rights reserved.
n Corresponding authors.
E-mail addresses: ssgross@med.cornell.edu (S.S. Gross),
brvnlou@rockefeller.edu (A.H. Brivanlou).
1 These authors contributed equally to this work.
Developmental Biology 391 (2014) 230–240
et al., 2006; Liot et al., 2013), transcriptional regulation of a large
variety of genes (Cha, 2007; Seong et al., 2010; Zuccato et al.,
2001), mitotic spindle orientation (Godin et al., 2010), cell adhe-
sion (Lo Sardo et al., 2012), endocytosis and vesicular transport
(Metzler et al., 2001; Pardo et al., 2010; Qin et al., 2004; Smith et
al., 2009), neuronal survival and neurogenesis (Reiner et al., 1988,
2003; White et al., 1997). Additionally, Htt protein is present in
mitochondria of rat (Gutekunst et al., 1998), mouse, and human
somatic cells(Choo et al., 2004) and therefore, may be important
for mitochondrial activities. In human lymphoblasts, the ATP/ADP
ratio, a key measure of cellular energy reserves has been corre-
lated with the length of the poly-Q extension in Htt, even when
this length is in the normal range (Seong et al., 2005). This
apparent correlation raises the possibility that energy metabolism
modulation may be a normal cellular role of Htt, not just
a function acquired by the extension of the poly-Q region.
Although Htt plays a crucial role in both embryonic development
and disease initiation, the precise molecular and cellular functions
of Htt in early embryonic cells and in the brain remain unknown
(Woda et al., 2005). In particular, the connection between Htt and
metabolism during early development is essentially unexplored
to date.
In this study, we used global untargeted metabolite proﬁling to
compare the small molecule metabolome (50–1000 Da) of mutant
htt in mESC, both gain- and loss-of-function, in comparison with
the metabolome of wild-type mESCs. Our ﬁndings demonstrate
that htt mutation results in profound dysregulation of key meta-
bolic pathways during pluripotency. These studies reveal that
mouse htt / ESCs exhibit severe bioenergetic and metabolic
defects, including an essentially complete failure of mitochondrial
ATP generation, associated with defects in mitochondrial struc-
ture. Conversely, mutant mESCs with poly-Q (Q140/7) do not
exhibit apparent mitochondrial structural defects, but do show
metabolic alterations, including a higher respiratory capacity with
wild-type levels of nucleotide mono-, di- and tri-phosphates. Our
ﬁndings provide a molecular explanation for the early embryonic
lethality phenotype of the htt / mouse, and reveal a previously
unrecognized but essential role for Htt in supporting mitochon-
drial bioenergetics, metabolism and structural integrity during
early embryogenesis.
Materials and methods
Cell culture
Htt/ , Htt-Q7/7, and Htt-Q140/7 mES cells were provided by
Dr. Scott Zeitlin (University of Virginia) and propagated on 0.1%
gelatin-coated plates, under serum- and feeder-free culture con-
ditions in medium containing a 1:1 mix of DMEM-F12 (Invitrogen
Cat# 12634) and neurobasal medium (Invitrogen Cat# 21103),
supplemented with N2 (Invitrogen Cat# 17502), B27 supplement
without Vitamin A (Invitrogen Cat# 12587), 2 mM GlutaMAX
(Invitrogen Cat# 35050), 25 μg/ml of BSA (Invitrogen Cat#
15260), 10 μg/ml insulin (Sigma-Aldrich Cat# I9278), 0.1 mM β-
mercaptoethanol (Invitrogen Cat# 21985), 10 ng/ml LIF (Millipore
Cat# ESG1107), 0.5 μM PD0325901 (Axon Med Chem, Cat# Axon
1408) and 3 μM CHIR99021 (EMD Millipore, Cat# 361559). Cell
culture medium was changed daily and the cells were passaged by
trypsinization every 3 days.
Metabolite extraction for metabolomic analysis
Cells were grown in 6-well plates to 70% conﬂuency. Culture
medium and cells were collected separately for analysis by
untargeted metabolite proﬁling. For media analysis, the medium
was centrifuged at 1500 rpm for 10 min at 4 1C to remove dead
cells and debris; supernatants were collected and frozen at 80 1C
until the day of analysis. For analysis, media metabolites were
directly extracted in 1:200 vol:vol 70% acetonitrile and aqueous
0.2% ammonium hydroxide and 3 ml of this extract was subjected
to untargeted metabolite proﬁling by LC/MS. For analysis of
cellular metabolites, cells were quickly washed twice with ice-
cold PBS, followed by metabolic quenching and metabolite extrac-
tion using 70 1C 80:20 methanol:water (LC-MS grade methanol,
Fisher Scientiﬁc). Cold-quenched cells were scrape-harvested
using a teﬂon cell scraper and transferred with 80% cold MeOH
to 2.0 ml Tissuelyzer tubes (Qiagen). The cell–MeOH mixtures
were incubated on dry ice for 10 min then subjected to bead-
beating for 45 sec using a Tissuelyser cell disrupter (Qiagen).
Extracts were centrifuged for 5 min at 5000 rpm to pellet inso-
luble material and supernatants were tranfered to clean tubes.
This extraction was repeated two additional times and all three
supernatants were pooled, dried in a speed-vac (Savant) and
stored at 80 1C until analysis. For normalization of sample
analyses, post-extracted cell pellets were solubilized in 200 ml
0.2 M aqueous NaOH at 95 1C for 20 min and the pellet protein
was quantiﬁed using the BioRad DC assay. On the day of metabo-
lite analysis, dried cell extracts were reconstituted in 70% acetoni-
trile with 0.2% ammonium hydroxide at a relative protein
concentration of 8 mg/ml and 3 ml of this reconsitued extract was
injected for LC/MS-based untargted metabolite proﬁling.
Untargeted metabolite proﬁling
Both cell and culture medium extracts were analyzed by LC/MS
essentially as described previously (Chen et al., 2012), using
a platform comprised of an Agilent Model 1200 liquid chromato-
graphy system coupled to an Agilent Model 6230 time-of-ﬂight MS
analyzer. Metabolite separation was performed by using aqueous
neutral phase gradient chromatography on a Diamond Hydride
column (Microsolv) and mobile phases as follows: (A) 50% iso-
propanol, containing 0.025% acetic acid, and (B) 90% acetonitrile
containing 5 mM ammonium acetate. Raw data were analyzed
using Agilent MassHunter Qual software, and Mass Proﬁler Profes-
sional software. Brieﬂy, Qual performs untargeted molecular
feature extraction to generate compounds/metabolites based on
the elution proﬁle at identical mass and retention times within
a speciﬁed mass accuracy (5 ppm). Aligned molecular features
detected in all biological replicates from at least one cell group
(i.e., htt / , Htt-Q140/7 mutant and Htt-Q7/7 wild-type) were
directly applied for statistical analysis across treatment groups by
Mass Proﬁler Professional. The Bonferroni family-wise-error-rate
correction was applied for multiple testing correction of p-values
(corrected for po0.05).
Differentially expressed metabolite identiﬁcation
Differentially expressed metabolites in htt mutant mESC, with
fold-changes greater than 2.0 (po0.05), compared to htt wild-
type mESC, were searched against an in-house annotated METLIN
Personal Metabolite Database (Agilent Technologies), based on
accurate monoisotopic neutral masses (o5 ppm). A molecular
formula generator (MFG) algorithm in MPP was used to generate
and score empirical molecular formulae based on a weighted
consideration of monoisotopic mass accuracy, isotope abundance
ratios, and spacing between isotope peaks. A putative compound
ID was tentatively assigned when METLIN and MFG scores con-
curred for a given candidate molecule. Tentatively assigned com-
pound identities were assigned and veriﬁed based on a match of
LC retention times and/or MS/MS fragmentation spectra to that of
pure molecule standards in our progressively growing database.
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Mitochondrial oxygen consumption and glycolysis-derived
lactate ﬂux
Glycolysis and oxidative phosphorylation ﬂux analysis was
performed using kits from Seahorse Biosciences, in accord with
the manufacturer's recommendations. For these assays, cells were
seeded on XF96 cell culture microplates (Seahorse Biosciences
Cat# 101085-004) and grown to 70% conﬂuency prior to analysis.
On the day of assay, culture media were changed to XF Assay
medium (Seahorse Biosciences Cat# 102365-100), supplemented
with 5 g/L of glucose, 2 mM glutamine, and 2 mM pyruvate for
oxidative phosphorylation assay and supplemented with only
2 mM pyruvate for assay of glycolysis rates. Prior to assay, plates
were transferred into a non-CO2 incubator at 37 1C and kept for
1 h. To quantify oxidative phosphorylation rates, we ﬁrst measured
initial (basal) oxygen consumption rates, followed by a series of
changes in oxygen consumption when cells were sequentially
treated with 2.5 μM oligomycin, 0.75 μM FCCP, and ﬁnally a
combination of 1 μM rotenone and 1 mM antimycin. Following
each addition, oxygen levels in the culture medium were mon-
itored at 20 s intervals and the overall oxygen consumption rate
(OCR) was calculated. For the glycolysis stress test, after collecting
baseline acidiﬁcation rate (lactate release) data, cells were sequen-
tially treated with 10 mM glucose, 1 mM oligomycin, and 100 mM
2-deoxy-glucose and evoked changes in acidiﬁcation rate were
quantiﬁed after each addition. For this purpose, changes in culture
medium pH was monitored every 20 s and used to calculate the
overall extracellular acidiﬁcation rate (ECAR).
Measurement of mitochondrial abundance
Mitotracker Red dye (Invitrogen, Cat# M7512) was used for the
measurement of mitochondrial abundance. Cells were trypsinized
and 105 cells were treated with Mitotracker Red dye (50 nM) in the
mESC medium at 37 1C for 30 min. After incubation, the cells were
spun down, washed with medium, resuspended in PBS containing
0.5% bovine serum albumin and then analyzed for ﬂuorescence by
ﬂow cytometry. Flow cytometry analysis was performed using
a BD LSRII instrument at Rockefeller University Flow Cytometry
core facility.
Western blot analysis
Whole cell lysate was harvested using trypsin/EDTA and lysed
in RIPA buffer containing protease inhibitors (Roche, 11-836-170-001)
and PMSF (1 mM). Lysate was centrifuged at 413,000 g for 10 min at
4 1C. Protein concentrations of lysate were measured by Bradford
assay (Bio-Rad) and 60 μg total protein was loaded. Westerns were
performed using the Novex NuPage SDS-PAGE blot system. Blots
were probed with anti-cytochrome c (Millipore, #MAB1800), anti-
cytochrome b-c1 subunit RISP (Millipore, #ABC322), anti-VDAC
(Millipore, #MABN504), or anti-actin (Cell Signaling, #3700).
Measurement of mitochondrial membrane potential
A mitoprobe JC-1 assay kit (Invitrogen, Cat# M34152) was used
for the measurement of mitochondrial membrane potential
according to manufacturer's instructions. Brieﬂy, the cells were
trypsinized, 105 cells were resuspended in mESC medium, treated
with 2 μM JC-1 at 37 1C for 30 min, washed and resuspended for
ﬂuorescence analysis by ﬂow cytometry. TMRE (Invitrogen T-699)
and MitoTracker DeepRed (Invitrogen M22426) co-staining, cells
were trypisinized, washed twice with growth medium and incu-
bated in medium containing TMRE (200 nM) and/or MitoTracker
DeepRed (200 nM) for 30 min at 37 1C for 30 min. After incubation,
cells were washed twice with media, resuspended in PBS and
analyzed using a BD FACSArray instrument.
Electron microscopy
Cells were seeded on 6-well plates and grown to 90% con-
ﬂuence. The plates were processed according to previously pub-
lished protocols (Cohen-Gould, 2013) and imaged at the Weill
Cornell Medical College EM core facility. Mitochondria were
counted blind using 4200 mitochondria from EM images. ‘Good’
mitochondria were regular in shape, had deﬁned outer membrane
and well-developed cristae. ‘Poor’ mitochondria were those deter-
mined to have an irregular shape, compromised outer membrane,
abnormal cristae, and/or a ‘vesicular’ morphology.
Results
Comparative metabolite proﬁling of htt / and htt-Q140/7 in
embryonic stem cells
To broadly discover metabolic consequences in both htt / and
Htt-Q140/7 mutant mouse stem cells, we performed untargeted
liquid chromatography/mass spectrometry (LC/MS)-based meta-
bolite proﬁling and compared to ﬁndings with wild-type Htt-Q7/7
stem cells. This analysis contrasted metabolite proﬁles in three
syngeneic cell lines that differ only with regard to their htt
genotypes when cultured under pluripotency conditions (see
Materials and methods section). Proﬁling data were acquired using
aqueous neutral phase LC and both negative-ion and positive-ion
MS detection for broad coverage of potential changes in hydro-
philic metabolite levels that contribute to intermediary metabo-
lism. Together, this metabolomic analysis surveyed 3758 molecular
features of 50–1000 Da mass/charge (m/z), considering only mole-
cules that were detected in all biological replicates from at least
one genetic group. Each genetic group comprised 9–10 replicate
mESC cultures (Fig. S1). Notably, 1384 species were quantiﬁed as
negative ions (Fig. S1A) and 2374 species were detected as positive
ions (Fig. S2A). Principal component analysis (PCA) and unsuper-
vised hierarchical cluster analysis (HCA) revealed within-group
clustering and between-group separation of metabolites in sam-
ples prepared from each of the three different cell lines (Figs. S1B
and C and S2B and C). Considering the 1384 species observed as
negative ions, levels of 60 metabolites in htt / and 164 species in
Htt-Q140/7 were signiﬁcantly altered when compared to Htt-Q7/7
(po0.05 and fold-changeZ2.0; Fig. S1D). Among these, 30
differences from Htt-Q7/7, overlapped between both htt/ and
Htt-Q140/7 mutants (Fig. S1D and Table S1). A signiﬁcant and
marked effect of htt mutants on metabolite expression levels was
similarly observed with positive ion detection, where 62 species in
htt / and 192 species in Htt-Q140/7 differed signiﬁcantly from
Htt-Q7/7 (po0.05 and fold-changeZ2.0; Fig. S2D). Together,
these ﬁndings establish that both htt / and Htt-Q140 mutations
profoundly perturb metabolism in pluripotent embryonic
stem cells.
htt / mESCs display accelerated glycolysis and ketogenesis
Despite the relative inefﬁciency of aerobic glycolysis for ATP
generation, as compared to ATP generation by mitochondrial
respiration, aerobic glycolysis is the predominant bioenergetic
phenotype for rapidly proliferating cells (e.g., cancer cells) and is
also typical of pluripotent embryonic stem cells (Folmes et al.,
2012). A hallmark feature of aerobic glycolysis is increased glucose
uptake and accelerated metabolism to pyruvate, followed by
NADH-mediated reduction to lactate and extracellular export.
I. Ismailoglu et al. / Developmental Biology 391 (2014) 230–240232
To assess whether htt mutations are associated with an altered
rate of glycolysis, we compared relative levels of glucose, lactate,
and pyruvate, both intracellularly and in 24 h cell culture medium.
Interestingly, htt / mutants displayed signiﬁcantly increased
levels of lactate, both intracellularly and extracellularly, compared
to Htt-Q7 and Htt-Q140 (Fig. 1). Conversely, lactate release into the
cell culture medium was relatively diminished in Htt-Q140/7
mutant cells. In accord with a relatively accelerated rate of aerobic
glycolysis in htt / cells, the observed increase in lactate release
was associated with a reciprocal decrease in intracellular and
culture medium pyruvate levels (Fig. 1). Additionally, htt / cells
exhibited a 15–20% decrease in intracellular glucose and increased
glucose uptake from the culture medium, when compared with
normal Htt-Q7/7 and mutant Htt-Q140/7 cells, consistent with
enhanced glucose consumption for aerobic glycolysis (Fig. 1).
These ﬁndings demonstrate that htt / mutation in mESC is
associated with a metabolic switch toward increased aerobic
glycolysis.
Targeted metabolite proﬁling of data described in Figs. S1 and
S2, conﬁrmed by chromatographic retention time and MS/MS
fragmentation of standards, provided for a broad assessment of
the effects of htt mutations on metabolic pathway intermediates,
including those of glycolysis and the Krebs cycle (Fig. S3). Notably,
whereas htt / mutants showed a signiﬁcant decrease in levels of
glycolytic hexose intermediates (glucose-6-phosphate and fruc-
tose 1,6-diphosphate), all glycolytic triose intermediates except
pyruvate increased in abundance. This ﬁnding is consistent with
accelerated use of glucose for glycolysis, resulting in build-up of
triose intermediates, increased pyruvate reduction to lactate and
efﬂux of lactate into the culture medium. Increased conversion of
pyruvate to lactate, in lieu of reductive decarboxylation by pyr-
uvate decarboxylase to acetyl CoA for subsequent entry into the
Krebs cycle, is in accord with more than 50% decrease in acetyl
CoA levels observed in htt / mESCs (Fig. S3B). In contrast, acetyl
CoA levels were increased by almost 2-fold in Htt-Q140/7 cells
(Fig. S3B). It is notable that β-oxidation of lipids provides an
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Fig. 1. Measurement of relative levels of glucose, lactate and pyruvate in cells and cell culture medium indicates an increased rate of glycolysis in htt / mESCs, but no
signiﬁcant effect of Htt-Q140/7 mutation. Bars depict relative ion abundances measured by LC-MS for the indicated metabolites, measured both in cells (left panels) and in
culture media (right panels). Observed fold-changes and p-values are quantiﬁed for htt / mESC (green bars) and Htt-Q140/7 mutant mESC (red bars), in comparison with
wild-type Htt-Q7/7 mESC (yellow bars). Error bars are SEM. (For interpretation of the references to color in this ﬁgure caption, the reader is referred to the web version of this
paper.)
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additional source of acetyl CoA for entry into the Krebs cycle,
beyond that provided by glycolysis. However, insufﬁcient catabolic
consumption of acetyl CoA by the Krebs cycle can promote acetyl
CoA condensation reactions that result in accumulation of ketone
body products, including acetoacetic acid and β-hydroxybutyric
acid. We observed that htt / cells exhibit a signiﬁcant accumula-
tion of these ketone bodies intracellularly and release ketones and
hydroxyacids into the cell culture medium (Fig. S4). It is notable
that although Htt-Q140/7 mESC did not exhibit altered levels of
nucleotide mono-, di-, and tri-phosphate levels relative to wild-
type Htt-Q7/7 mESC, other metabolite levels were signiﬁcantly
altered – this included changes in nucleotide bases, lipid proﬁles,
carnitines, sulfur metabolites and some amino acids (Fig. S5).
Taken together, these ﬁndings demonstrate that metabolism in
both htt / and Htt-Q140/7 mESCs is profoundly aberrant; in the
case of htt / mESC this perturbation is characterized by an
increased rate of aerobic glycolysis and failure to efﬁciently oxidize
acetyl CoA by the Krebs cycle.
htt / mESCs are depleted of intracellular nucleotide triphosphates
Our ﬁnding of a ketogenic metabolism in htt / mESCs
suggests impaired NADH production for support of ATP generation
by aerobic respiration in mitochondria. Since glycolysis is far less
bio-energetically efﬁcient than aerobic respiration (2 vs. 36 mols
ATP/mole glucose generated), we wondered whether htt / muta-
tion may be associated with a relative bioenergetic deﬁcit, reﬂected
in decreased ATP/AMP and ATP/ADP ratios. To test this possibility,
untargeted negative ion proﬁling data were assessed for relative
levels of adenine nucleotide tri-, di-, and mono-phosphates in htt /
relative to Htt-Q7/7 and Htt-Q140/7 cells (Fig. 2). Notably, htt /
cells exhibited a 50% decrease in ATP levels, concomitant with 2-fold
increases in both ADP and AMP levels, compared to both Htt-Q7/7
and Htt-Q140/7. This relative energetic collapse observed in htt /
cells for adenine nucleotides extended to other nucleotides of the
guanine, cytosine, thymidine, and uridine mono-, di-, and tri-
phosphate series. Indeed, levels of GTP, CTP, TTP and UTP were all
decreased signiﬁcantly in htt / compared to Htt-Q7/7 cells, con-
comitant with reciprocal increases in cognate mono- and dipho-
sphate levels (with the sole exception of GDP, which remained
unchanged in htt / cells; Fig. 2). In sharp contrast to the profound
nucleotide tri-phosphate deﬁcit and monophosphate/diphosphate
increases in htt / mESC, nucleotide levels in Htt-Q140/7 were
indistinguishable from levels in Htt-Q7/7 cells. Dissipation of the
cellular reservoir of ATP and other nucleotide triphosphates in htt /
cells demonstrates that Htt protein activity is critical for the main-
tenance of high energy phospho-metabolites.
htt / mutation accelerates purine biosynthetic and salvage
pathways
Interestingly, examination of the 30 molecules that are differ-
entially expressed between htt/ and Htt-Q7/7 (Fig. S1D and
Table S1) led to the identiﬁcation of several molecules that are
uniquely expressed in htt / cells. One such unique molecule
(RT¼10.97 min, Mass¼295.0618 Da) was observed to have a
formula consistent with C8H14N3O7P and was molecularly identi-
ﬁed as 5-aminoimidazole ribonucleotide (AIR, Fig. 3). AIR is
a pivotal intermediate in purine nucleotide biosynthesis, which
involves 10 enzymes for the ultimate conversion of phosphoribosyl
pyrophosphate to the ﬁrst purine metabolite, inosine monopho-
sphate. Examination of the relative abundance of all other inter-
mediates involved in this pathway revealed that in addition to AIR,
levels of ﬁve other purine biosynthetic intermediates were also
markedly increased in htt / vs. Htt-Q7/7 cells. Indeed, similar to
AIR, three out of ﬁve intermediates were only detected in htt /
cells – these include phosphor-ribosyl-formyl-glycineamidine
(FGAM), formamidoimidazole-4-carboxamide ribotide (FAICAR),
and 50-phosphoribosyl-4-(N-succinocarboxamide)-5-aminoimida-
zole (SAICAR). The two other differentially expressed purine
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Fig. 2. High-energy nucleotide tri-phosphate levels are signiﬁcantly decreased in htt / mESCs and nucleotide di- and mono-phosphate levels are signiﬁcantly increased, as
compared with Htt-Q7/7 control mESC. In contrast, Htt-Q140/7 mutation does not alter the levels of nucleotide tri-, di- or mono-phosphates. Results are mean values 7SD
(n¼9–10). *A signiﬁcant difference with po0.05.
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pathway intermediates were 5-aminoimidazole-4-carboxamide
ribotide (AICAR, increased 7.1-fold) and the ﬁnal pathway product,
inosine monophosphate (IMP, increased 3.3-fold). In addition to
purine biosynthesis intermediates, all detected purine salvage path-
way metabolites and products were signiﬁcantly increased in htt /
cells, except for ATP and GTP, which signiﬁcantly decreased (Fig. 2).
Together, these results reveal a substantial acceleration of purine
synthesis and turnover in htt / mESCs, suggesting the operation
of a biochemical regulatory mechanism that increases purine
biosynthesis, potentially as compensation for the relative paucity
of ATP, GTP and other nucleotide triphosphates in htt / mESC.
Htt protein activity is necessary for mitochondrial ATP synthesis
AMP-activated protein kinase (AMPK) serves as a master switch
that regulates cellular bioenergetics, including an activation of
glucose uptake and accelerated glycolysis (Yuan et al., 2013). Since
AMPK is allosterically activated in cells in response to an elevated
ratio of AMP/ATP as well as by direct binding of the AMP analog
AICAR (Merrill et al., 1997), both of which were increased in htt /
cells, we considered whether htt / cells favored glycolysis over
mitochondrial respiration as an ATP source. To directly test this
possibility, both mitochondrial and glycolysis respiration rates
were measured in all three mESC lines using an extracellular ﬂux
analyzer. Results showed that htt / cells consume 70% less
oxygen compared to wild-type Htt-Q7/7 cells. In contrast, Htt-
Q140/7 mESC displayed a relative 50% increase in oxygen con-
sumption. Because oxygen consumption by htt / mESC was not
decreased by the selective mitochondrial ATP synthase inhibitor,
oligomycin, it is apparent that htt / mESC mitochondria do not
contribute to ATP synthesis. This is in contrast to a marked degree
of oligomycin-inhibited mitochondrial ATP synthesis in both Htt-
Q7/7 and Htt-Q140/7 mESC.
To investigate whether htt / impairs electron transfer
through the mitochondrial respiratory complexes, we measured
the maximal respiratory capacity of htt / mESC for support of
Fig. 3. There is a marked intracellular accumulation of metabolites of de novo purine biosynthesis and purine salvage pathways in htt / compared with Htt-Q7/7 wild-type
and Htt-Q140/7 mutant mESCs. The colors of fonts denote metabolites in htt / mESC with abundances that are signiﬁcantly increased (red), decreased (blue), unchanged
(black) and undetected (gray), in comparison with Htt-Q7/7 mESC. For each observed change, the measured p-values and fold-changes are given. *Denotes a signiﬁcant
difference with po0.05. The nomenclature for labeling of metabolic enzymes (names given adjacent to pathway arrows) is from the Kyoto Encyclopedia of Genes and
Genomes (KEGG) pathway map. Abbreviations: PPAT, phosphoribosyl pyrophosphate amidotransferase; GART, phosphoribosylglycinamide formyltransferase; PFAS,
phosphoribosylformylglycinamidine synthase; PAICS, phosphoribosylaminoimidazole carboxylase; ADSL, adenylosuccinate lyase; ATIC, 5-aminoimidazole-4-carboxamide
ribonucleotide formyltransferase; GMPS, guanine monphosphate synthetase; GUK, guanylate kinase; NME, nucleoside diphosphate kinase; 50-NT, 50-nucleotidase; PNP,
purine nucleoside phosphorylase; AMPD, adenosine monophosphate deaminase; AK1, adenylate kinase 1; NME7, NME/NM23 family member 7. (For interpretation of the
references to color in this ﬁgure caption, the reader is referred to the web version of this paper.)
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oxidative phosphorylation. Toward this end, we studied the effect
of the mitochondrial uncoupling agent, carbonylcyanide-4-(tri-
ﬂuorometoxy)-phenylhydrazine (FCCP), on cellular oxygen con-
sumption. Treatment of htt / cells with FCCP elicited a very
modest increase in oxygen consumption, indicative of a minimal
mitochondrial respiratory capacity (Fig. 4). In contrast, Htt-Q140/7
mESC exhibited an apparently accelerated rate of mitochondrial
ATP synthesis, compared to Q7/7 mESC, and additionally exhibited
a greater mitochondrial respiratory reserve (Fig. 4A). Together,
these results suggest htt gene expression is essential for mito-
chondrial ATP synthesis and respiratory chain function and Htt
mutations can alter mitochondrial bioenergetic capacities.
To test if htt / cells alter their rate of glycolysis-derived ATP in
compensation for an apparent lack of mitochondrial ATP genera-
tion, extracellular acidiﬁcation rate (ECAR) was quantiﬁed to
assess glycolytic ﬂux. After equilibrating mESC cell lines with
glucose-free culture medium, 10 mM glucose was added to acti-
vate glycolysis and ECAR was quantiﬁed. While the glycolytic rate
of Htt-Q7/7 and Htt-Q140/7 mESCs was essentially indistinguish-
able, htt / cells displayed an E2-fold greater rate of glycolysis
(Fig. 4B). Upon inhibition of oxidative phosphorylation with
oligomycin, mESC lines responded with the anticipated increase
in glycolysis, offsetting the elicited inhibition of mitochondria-
derived ATP generation and revealing the cells maximal capacity
for glycolysis. Whereas ECAR measurements demonstrated large
and essentially identical glycolytic reserve capacities for both Htt-
Q7/7 and Htt-Q140/7, htt / mESCs exhibited no detectable
glycolysis reserve capacity whatsoever (i.e., cells were already
operating at a maximum glycolytic rate prior to oligomycin
treatment). A ﬁnal addition of 2-deoxy-glucose to all cell lines
resulted in a rapid and near-complete decrease in ECAR, conﬁrm-
ing that the measurements were indeed due to glycolysis-derived
lactate release. Taken together, these studies indicate that htt /
mESCs are incapable of mitochondrial ATP synthesis and instead
continuously generate ATP at near maximal capacity by glycolysis,
without any apparent functional reserve.
Electron microscopy shows severe structural problems
in htt / mitochondria
Studies were performed in order to determine whether the
failure of mitochondrial production of ATP in htt / mESCs is
associated with conspicuous alterations in mitochondrial abun-
dance, structural integrity, or functional capacity. In one line of
investigation, electron microscopy (EM) was employed to compare
structural features of mitochondria in the three mESC lines.
Interestingly, EM images revealed that many mitochondria in
htt / mESC are structurally abnormal exhibiting a relative
paucity of cristae compared to Htt-Q7/7 and Htt-Q140/7 lines
(Fig. 5A–G). Additionally, mitochondria in htt/ mESC exhibited
fragmentation, suggestive of initial stages of autophagy (as indi-
cated by the loss of inner membrane structure) (Kubli and
Gustafsson, 2012) (Fig. 5B). These ﬁndings reveal that mitochon-
dria are structurally aberrant in the absence of Htt protein.
We next assessed whether relative mitochondrial abundances
differed in htt / , Htt-Q140/7, and Htt-Q7/7 mESC. Toward this
end, mitochondrial abundance was compared on a per cell basis
using FACS analysis, based on the mitotracker dye. Results demon-
strated similar average ﬂuorescence levels in all three cell lines
(Fig. 5H), indicating similar mitochondrial abundances and that
loss of mitochondria from htt / mESCs does not explain their
relatively low levels of total ATP and the apparent inability of
mitochondria from these cells to produce ATP. We next took whole
cell lysate from all three lines and probed for relative expression
levels of the mitochondria speciﬁc proteins VDAC1, RISP (cyto-
chrome b-c1 subunit 5), and cytochrome c. Results demonstrated
that levels of these proteins across all three lines were indis-
tinguishable (Fig. 5I).
Based on the mitochondrial structure perturbation in htt /
cells, we next investigated the functional capacity of htt / cells to
maintain their normal membrane potential. Toward this end, we
used the ﬂuorescent dyes JC-1 and TMRE as relative indicators of
inner mitochondrial membrane potential. The greater the mem-
brane potential the more the JC-1 and TMRE aggregation within
mitochondria, and this is revealed by distinct ﬂuorescence emis-
sion signals. In JC-1 experiments, a mitochondrial uncoupling
agent (CCCP) was used as a control, for quantiﬁcation of ﬂuores-
cence emission upon complete dissipation of the electrical poten-
tial across the mitochondrial inner membrane. As expected,
treatment of cells with CCCP resulted in a complete loss of the
JC-1 aggregate ﬂuorescence signal (Fig. 5J). In TMRE experiments
(Fig. 5K), we additionally utilized the mitotracker dye to measure
the abundance of mitochondria in relation to their membrane
potential (Fig. 5L). Surprisingly, results of these studies revealed
that the mitochondrial membrane potential was completely pre-
served in htt / cells, despite their apparently complete loss of
ATP-generating capacity (Fig. 4A), and conspicuous structural
deﬁcits (Fig. 5B). In fact, the mitochondrial membrane potential
was similar in all three lines (Fig. 5J–L). Paradoxically, we noted
Fig. 4. Inﬂuence of htt / and Htt-Q140/7 mutations on mitochondrial and
glycolytic ﬂuxes in mESCs. (A) Mitochondrial ATP synthesis rate, based on the
oligomycin-inhibited oxygen consumption rate (OCR). At the indicated time,
oligomycin was added to reveal the extent to which oxygen is being consumed
for ATP synthesis. FCCP, an uncoupler of mitochondrial respiration was subse-
quently added to deﬁne the maximal capacity of cells for mitochondrial respiration.
Finally, the combination of rotenone and antimycin was added to elucidate total
mitochondrial oxygen consumption. Results demonstrated that ATP synthesis and
synthetic capacity are dramatically impaired in htt / mESC, while ATP production
rate and capacity are relatively increased in Htt-Q140/7 cells. (B) Glycolysis rate,
based on the glucose-dependent extracellular acidiﬁcation rate (ECAR). Initially,
cells are in the glucose-free medium, followed by the addition of glucose at the
indicated time. Oligomycin is subsequently added to block mitochondrial respira-
tion and reveals the glycolytic reserve capacity (i.e., maximal rate of glycolysis).
Finally, an inhibitor of glycolysis, 2-deoxyglucose (2-DG), is added to ascertain the
extent to which OCR derives from glycolysis. These results demonstrate that htt /
mESC conduct glycolysis at a near-maximal rate for energy production. In both
panels, points depict mean values for eight replicate determinations ±SEM.
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that the Htt / actually exhibits fewer depolarized mitochondria
compared to either Htt-Q7/7 or Htt-Q140/7 (Fig. S6). These results
demonstrate that failure of ATP production in htt / cells is not
associated with a diminished abundance or relative loss of inner
mitochondrial membrane polarization, but is associated with
a loss of structural integrity.
Discussion
The early embryonic lethality of htt / mice reveals an essen-
tial role for Htt in the mammalian development. However, despite
decades of investigation focused on elucidating the basis for
neurotoxicity of mutant Htt protein, the fundamental role of
wild-type Htt remains unknown. In the present study we sought
to deﬁne the broad impact of htt / and Htt-Q140/7 mutants
on cell metabolism in pluripotent mESCs, a model of early
development. Toward this end, we performed an untargeted
metabolite proﬁling study in attempt to uncover differences in
mESC in three syngeneic lines. Our ﬁndings demonstrate that
extensive metabolic aberrations occur in both htt / and Htt-
Q140/7, compared with Htt-Q7/7 mESCs. Most notable among
these aberrations was a profound energy deﬁcit in htt / cells,
indicated by decreases in all nucleotide tri-phosphate (NTP) levels,
along with reciprocal increases in nucleotide di- and mono-
phosphate levels. In Htt-Q140/7 mESC, on the other hand, NTP
levels were not markedly impacted although other energy meta-
bolites are altered (Fig. S5). This is consistent with the ﬁndings
that patients with HD do not show a drastically altered ATP
concentration (Arning et al., 2010). It is thought that downstream
modiﬁers inﬂuence the role mutant Htt plays in energy metabo-
lism in the cell. Mitochondrial and glycolytic ﬂux measurements in
htt / mESCs showed that NTP deﬁcits were in conjunction with
an essentially complete failure of ATP production via oxidative
phosphorylation and compensatory acceleration of glycolysis-
derived ATP production. Our ﬁndings strongly suggest that
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Fig. 5. Mitochondrial EM structure is profoundly aberrant in htt / , relative to Htt-Q7/7 mESCs, whereas neither mitochondrial abundance nor membrane potential is
signiﬁcantly affected. (A–F) EM images at 15,000 (top panels), and 60,000 (bottom panels) comparing htt / (A and B), Htt-Q7/7 (C and D), and Htt-Q140/7 (E and F)
mESC. Results reveal profound structural aberrations in htt / mESC, indicative of loss of inner membrane cristae. Scale bars are shown at lower right. (G) Counts from EM
images of healthy (good) and unhealthy (poor) mitochondria show htt / mESC have more poor quality mitochondria. Mitochondria were counted in a blind manner. Results
are shown as the average number of mitochondria per image. Error bars are SEM. (H) Relative mitochondrial abundance in htt / and Htt-Q140/7 mESCs, compared with
wild-type Htt-Q7/7 mESCs, expressed on a per cell basis. Selective staining with MitoTracker red ﬂuorescent dye, followed by FACS analysis was used to assess relative
mitochondria abundance. Fluorescence values are given as mean values 7 SD. Notably, MitoTracker ﬂuorescence was indistinguishable for all three htt mESC lines tested.
(I) Equivalent mitochondrial abundance is shown by western blot analysis of whole cell lysate of htt / , Htt-Q7/7, and Htt-Q140/7 for the mitochondrial protein VDAC1,
cytochrome b-c1 subunit RISP, and cytochrome c. Equal amounts of protein were loaded and actin were used as controls. (J) Mitochondria from htt / mESC are polarized
like mitochondria from Htt-Q7/7 and Htt-Q140/7 mESCs. FACS analysis assessed mitochondria potential after staining htt / , Htt-Q140/7 and Htt-Q7/7 mESCs with the
mitochondrial voltage-sensitive ﬂuorescent dye, JC-1. Negative control with the mitochondrial uncoupling agent CCCP depicts ﬂuorescence spectral changes that occur when
the mitochondrial potential was eliminated. Notably, JC-1 ﬂuorescence results reveal polarization of mitochondria in all three htt lines. (K) Mitochondria from htt / mESC
are polarized like mitochondria from Htt-Q7/7 and Htt-Q140/7 mESCs. FACS analysis assessed mitochondria potential after staining htt / , Htt-Q140/7 and Htt-Q7/7 mESCs
with the mitochondrial voltage-sensitive ﬂuorescent dye, TMRE. (L) The ratio of polarization to the number of mitochondria is roughly equivalent between htt / , Htt-Q7/7
and Htt-Q140/7. Intensity levels of TMRE were divided by the intensity levels of MitoTracker.
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glycolysis may operate at a maximal rate in htt / mESC, leaving
no glycolytic reserve to accommodate increases in cellular energy
demands. Electron microscopic analysis of htt / mESCs further
revealed severe defects in mitochondrial structural integrity.
Taken together, these ﬁndings demonstrate that Htt protein is
necessary for both mitochondrial structure and function from the
earliest stages of embryogenesis.
It is notable that htt / embryos are smaller compared to their
wild type littermates and die by E7.5 with increased apoptosis
(Zeitlin et al., 1995). Defects in both the transfer of nutrition from
the visceral endoderm to the embryo (Dragatsis et al., 1998) and
a general aberration in forming and patterning of the primitive
streak have been suggested as the basis for embryonic death
(Woda et al., 2005). In view of the present metabolomic ﬁndings,
we propose that disruption of oxidative phosphorylation is, in fact,
the key driver of early developmental death of htt/ embryos.
Notably, htt / pluripotent mESCs are viable and exhibit a rate of
proliferation that is indistinguishable from syngeneic wild-type
Htt-Q7/7 cells. The viability of mESCs and pre-E7.5 embryos can be
explained by the predominant bioenergetic reliance on glycolysis,
allowing for survival despite the failed oxidative phosphorylation.
With further cell development and differentiation beyond E7.5,
however, mitochondrial-derived ATP becomes progressively
greater (Chung et al., 2007; Vempati et al., 2008; Wilding et al.,
2009; Baker and Ebert, 2013), offering a likely explanation for the
lethality phenotype of htt / mutant mouse.
In contrast to our ﬁnding that NTPs are preserved at their wild
type levels in Htt-Q140/7 mESCs, a recent investigation of htt
mutant mESCs observed a progressive decrease in ATP/ADP ratios
with increasing poly-Q lengths (studied to a maximal length of
Q111/7) (Jacobsen et al., 2011). Moreover, this study did not
observe the decrease in ATP/ADP that we found in htt / mESCs.
A likely explanation for our seemingly discrepant ﬁndings regards
culture conditions and cell growth details, including days in
culture, cell density at harvest, frequency of media changes and
culture media composition. Notably, the ability or inability of
glycolysis alone to support all ATP needs of the cell will predic-
tably be a function of whether the cells are expanding in rapid
growth phase or quiescent, whether the media are relatively rich
or poor, how frequently the cells are supplemented with fresh
media and in what quantity. In this regard, we recognize that the
above-mentioned study grew mESC in a serum-supplemented
medium, while we cultured cells in a deﬁned medium. One
possibility is that undeﬁned growth factors in serum compensate
for the loss of mitochondrial ATP generation by htt/ mESCs and
thereby cloak the phenotype we observed herein. Clearly, direct
metabolite proﬁling of htt / embryos will ultimately shed light
to this apparent contrast between the two studies. Unfortunately,
however, the number of mouse embryos required to perform such
a study is prohibitive with current technologies. We are currently
using CRISPR technology to generate htt / mutants in Xenopus
taking advantage of the fact that early embryogenesis (from the
fertilized egg onward) can be observed in a large number (hun-
dreds) of embryos to overcome this limitation. Direct imaging and
measurement of metabolomic proﬁles during very early stages of
Xenopus embryonic development will inevitably provide further
insights into the functions Htt in energy metabolism and in
generation of respiration competent mitochondria, in vivo.
Surprisingly, and despite signiﬁcant structural aberration, we
observed no signiﬁcant decrease in the abundance of mitochon-
dria in htt / or Htt-Q140/7 mESCs. It is also remarkable that
mitochondria from htt / mESC maintain their inner membrane
potential despite their apparent inability to contribute to ATP
generation. This unusual observation can be explained by one of
the two scenarios that we model in Fig. 6. In the ﬁrst scenario,
“normal” mitochondrial potential in htt / mESCs arises non-
autonomously, at the expense of extra-mitochondrial ATP (Fig. 6A).
In this case, membrane potential might be maintained through
reversed directionality of the mitochondrial ATP synthase complex
(complex V in Fig. 6), a phenomenon previously reported to occur
in some settings (Garedew et al., 2010). Thus, glycolysis-derived
ATP can be consumed for generation of a proton gradient (and
ADP) in the inner mitochondrial membrane by a reversed direc-
tionality of the ATP synthase complex – this would establish
a membrane potential and protect against cytotoxicity owing to
mitochondria-dependent apoptosis. If operational, a reversal of
ATP synthase directionality would require that glycolysis produces
not only enough ATP to meet cellular demands for biochemical,
mobility and transport processes, but would need to additionally
provide ATP for preservation of the mitochondrial potential and
hence, cell viability. Such a critical glycolytic demand for ATP
would predictably cause cells to exist in a fragile state, susceptible
to death by even modest transient increases in cell demands for
ATP. In the second scenario, Htt may act in a mitochondria
autonomous manner for coupling of the mitochondrial proton
gradient to ATP generation (Fig. 6B). If so, the absence of Htt would
limit dissipation of the mitochondrial membrane potential and
thereby promote the viability of cells despite an apparent failure in
mitochondrial ATP synthesis. From the two scenarios we currently
favor the ﬁrst. This is due to our observation that tagged-Htt when
Fig. 6. Schematic depicting two alternative models that may explain the existence of a mitochondrial inner membrane potential in htt / mESC, despite a lack of
mitochondrial ATP generation by these cells. The two models are distinguished as either arising via a mitochondria autonomous mechanism, wherein the respiratory
complexes generate a proton gradient, but ATP synthase is unable to effectively use this proton gradient for ATP production (left panel), or arising via a mitochondria non-
autonomous mechanism, wherein glycolysis-generated ATP serves to drive mitochondrial ATP synthase in reverse, resulting in a proton gradient at the expense of glycolysis-
derived ATP (right panel). Details of these models are considered in the text (adapted from Takeda et al., 2004).
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overexpressed in human embryonic stem cells (hESCs) fails to
localize to mitochondria, thus suggesting a non-autonomous effect
(data not shown). Regardless of the mechanism however, this
aspect of Htt function on mitochondria membrane potential was
unexpected and previously unnoticed. The construction of syn-
geneic htt / , and gain-of poly-Q mutants, currently in progress in
hESCs, and their comparison with wild-type cells, will allow
performing the same analysis directly in humans. The comparison
of the three human lines will identify metabolomic differences,
and comparison of the human and mouse htt-mutants data sets
will allow for a clear distinction between evolutionarily conserved
and specie-speciﬁc differences between human and mouse.
We show that Htt-Q140/7 mutant that models HD do not
display a defect in mitochondrial ATP synthesis in embryonic cells.
In mature neurons, however, HD clearly leads to mitochondrial
ATP deﬁcit and cell death. Therefore, an interesting and unresolved
question is: at what point of development does the initial damages
from gain-of poly-Q mutation that ultimately leads to HD becomes
cytotoxic? Providing the answer to this question at the cellular and
embryological level will provide important clues on the progres-
sion of HD, and inevitably have a strong impact in the rationale
design of HD treatments.
Finally, we note that mitochondrial biology is emerging as a key
focus point in understanding the cellular and molecular basis of
other neurodegenerative diseases. These include Alzheimer's dis-
ease (AD), Parkinson's disease (PD) and amyotrophic lateral
sclerosis (ALS) (Martin, 2012; Federico et al., 2012). In some
instances, mitochondrial function is hampered due to aberrant
protein–protein interactions that are disease speciﬁc. For example,
amyloid precursor protein (APP) has only been observed asso-
ciated with mitochondrial protein import channels TOMM40 and
TIMM23 in AD brains, not in controls (Devi et al., 2006; Bettayeb et
al., 2012). This interaction blocks transfer of proteins into the
mitochondria and perturbs energy metabolism (Bettayeb et al.,
2012). Similarly, certain mutants of SOD1 cause inherited ALS by
associating with mitochondria and changing mitochondrial
respiratory rate (Ferri et al., 2006; Faes and Callewaert, 2011).
Mitochondrial dysfunction can also be caused by the loss of
normal protein function. For example, recessive mutations of
PINK1, a mitochondrial kinase, have been shown to cause early-
onset PD (Hatano et al., 2004). PINK1's interactions suggest that
this is due to disruption of mitochondrial trafﬁcking (Weihofen et
al., 2009). While the impact of a gain-of-poly-Q mutant Htt protein
on mitochondria has been previously noticed in mature neuronal
cells (Bossy-Wetzel et al., 2008; Browne, 2008), we currently have
a very little understanding of how the loss or impairment of
normal Htt activity contributes to HD pathology (Mochel and
Haller, 2011). Our study demonstrates that Htt protein is necessary
for the maintenance of mitochondrial structure and function, and
thus links HD to a panel of neurodegenerative conditions that are
either caused by or arise in conjunction with aberrant mitochon-
dria. Understanding the molecular bases that connect Htt to
mitochondrial function will provide novel insights into mitochon-
drial biogenesis and may translate into unanticipated strategies for
therapeutic intervention in HD patients.
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